JAGUAR HEALTH, INC. Number of Reportable Segments
JAGUAR HEALTH, INC. (JAGX) reported Number of Reportable Segments of 2 Segment for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-19.
Financial Statements › Notes › Segment Reporting
us-gaap:NumberOfReportableSegments · last filed 2026-08-19
- JAGUAR HEALTH, INC. number of reportable segments for the quarter ending 2024-03-31 was 2.00 segment, a 0.00% change year-over-year.
- JAGUAR HEALTH, INC. number of reportable segments for the quarter ending 2023-03-31 was 2.00 segment, a 0.00% change year-over-year.
- JAGUAR HEALTH, INC. number of reportable segments for the quarter ending 2022-03-31 was 2.00 segment, a 0.00% change year-over-year.
- JAGUAR HEALTH, INC. number of reportable segments for the quarter ending 2021-03-31 was 2.00 segment, a 0.00% change year-over-year.
- JAGUAR HEALTH, INC. number of reportable segments for fiscal 2023 was 2.00 segment, a 0.00% change from fiscal 2022.
- JAGUAR HEALTH, INC. number of reportable segments for fiscal 2022 was 2.00 segment, a 0.00% change from fiscal 2021.
- JAGUAR HEALTH, INC. number of reportable segments for fiscal 2021 was 2.00 segment, a 0.00% change from fiscal 2020.
- JAGUAR HEALTH, INC. number of reportable segments for fiscal 2020 was 2.00 segment, a 0.00% change from fiscal 2019.
segment
| Period end | Number of Reportable Segments 3 month | Number of Reportable Segments 6 month | Number of Reportable Segments 9 month | Number of Reportable Segments 12 month |
|---|---|---|---|---|
| 2024-06-30 | 2.00 segment 10-Q · filed 2024-08-13 | |||
| 2024-03-31 | 2.00 segment 10-Q · filed 2024-05-14 | |||
| 2023-12-31 | 2.00 segment 10-K · filed 2024-04-01 | |||
| 2023-09-30 | 2.00 segment 10-Q · filed 2023-11-14 | |||
| 2023-06-30 | 2.00 segment 10-Q · filed 2023-08-14 | |||
| 2023-03-31 | 2.00 segment 10-Q · filed 2023-05-15 | |||
| 2022-12-31 | 2.00 segment 10-K · filed 2023-03-24 | |||
| 2022-09-30 | 2.00 segment 10-Q · filed 2022-11-14 | |||
| 2022-06-30 | 2.00 segment 10-Q · filed 2022-08-22 | |||
| 2022-03-31 | 2.00 segment 10-Q · filed 2022-05-10 | |||
| 2021-12-31 | 2.00 segment 10-K · filed 2022-03-11 | |||
| 2021-09-30 | 2.00 segment 10-Q · filed 2021-11-17 | |||
| 2021-06-30 | 2.00 segment 10-Q · filed 2021-08-13 | |||
| 2021-03-31 | 2.00 segment 10-Q · filed 2021-05-17 | |||
| 2020-12-31 | 2.00 segment 10-K · filed 2021-03-31 | |||
| 2020-09-30 | 2.00 segment 10-Q · filed 2020-11-16 | |||
| 2020-06-30 | 2.00 segment 10-Q · filed 2020-08-13 | |||
| 2020-03-31 | 2.00 segment 10-Q · filed 2020-05-15 | |||
| 2019-12-31 | 2.00 segment 10-K · filed 2020-04-03 | |||
| 2018-12-31 | 2.00 segment 10-K · filed 2019-04-10 | |||
| 2018-09-30 | 2.00 segment 10-Q · filed 2018-11-19 | |||
| 2018-06-30 | 2.00 segment 10-Q · filed 2018-08-13 | |||
| 2018-03-31 | 2.00 segment 10-Q · filed 2018-05-15 | |||
| 2017-12-31 | 2.00 segment 10-K · filed 2018-04-09 |
Segment
| Period end | Number of Reportable Segments 3 month | Number of Reportable Segments 6 month | Number of Reportable Segments 9 month | Number of Reportable Segments 12 month |
|---|---|---|---|---|
| 2026-06-30 | 2.00 Segment 10-Q · filed 2026-08-19 | |||
| 2025-12-31 | 2.00 Segment 10-K · filed 2026-04-07 | |||
| 2025-09-30 | 2.00 Segment 10-Q · filed 2025-11-14 | |||
| 2025-06-30 | 2.00 Segment 10-Q · filed 2025-08-14 | |||
| 2025-03-31 | 2.00 Segment 10-Q · filed 2026-05-20 | |||
| 2024-12-31 | 2.00 Segment 10-K · filed 2025-03-31 | |||
| 2024-09-30 | 2.00 Segment 10-Q · filed 2024-11-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Latigo Biotherapeutics, Inc. (LTGO) | United States | $1.176B | |
| LB PHARMACEUTICALS INC (LBRX) | United States | $1.220B | -10.87 |
| OPKO HEALTH, INC. (OPK) | United States | $1.220B | -15.59 |
| Seaport Therapeutics, Inc. (SPTX) | United States | $1.131B | |
| HARROW, INC. (HROW) | United States | $1.240B | -42.77 |
| Damora Therapeutics, Inc. (DMRA) | $1.250B | -6.10 | |
| Amphastar Pharmaceuticals, Inc. (AMPH) | United States | $1.116B | 10.93 |
| Avalyn Pharma Inc. (AVLN) | United States | $1.267B | |
| First Tracks Biotherapeutics, Inc. (TRAX) | United States | $1.280B | |
| Alto Neuroscience, Inc. (ANRO) | United States | $1.065B | -11.02 |